New drug duo aims to tackle tough lymphoma
NCT ID NCT06252675
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether combining glofitamab (an antibody that helps immune cells attack cancer) with pirtobrutinib (a pill that blocks cancer growth signals) is safe and effective for adults with mantle cell lymphoma that has come back or not responded to treatment. About 30 participants will receive the drugs along with standard imaging and blood tests. The study will monitor side effects and measure how many patients achieve complete remission.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
glofitamab and pirtobrutinib
What this could lead to
If it works, this could offer a new treatment option for people with mantle cell lymphoma that has returned or stopped responding to prior therapy.
What could go wrong
This is a small, early-phase trial (30 people) focused on safety and tumor response. The combination may cause serious side effects like cytokine release syndrome, and it is not yet known if it will improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, Davis
RECRUITINGDavis, California, 95616, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
University of California, Los Angeles
RECRUITINGLos Angeles, California, 90095, United States
Contact
Contact Email: •••••@•••••
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Email: •••••@•••••
Contact
Contact
Contact Email: •••••@•••••